NCT05401136 (HepC:CAC) is a clinical trial in Hepatitis C, Chronic, sponsored by Radboud University Medical Center.

Who is sponsoring NCT05401136?

NCT05401136 is sponsored by Radboud University Medical Center.

What condition does NCT05401136 study?

NCT05401136 studies Hepatitis C, Chronic, Substance Use Disorders.

Is NCT05401136 still recruiting?

NCT05401136 is currently status unknown. Last updated 2 June 2022.

Last reviewed 2022-06-02 · How we verify

NCT05401136: HepC:CAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Chain of Addiction Care (CAC)

Status unknown Last updated 2 June 2022

What this trial tests

trial in Hepatitis C, Chronic in 1,000 participants. Status unknown.

Timeline

1 March 2020

Primary endpoint
1 December 2023

1 December 2023

Quick facts

Lead sponsor	Radboud University Medical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	1 March 2020
Primary completion	1 December 2023
Estimated completion	1 December 2023
Sites	1 location across Netherlands

Conditions studied

Hepatitis C, Chronic — all drugs for Hepatitis C, Chronic →
Substance Use Disorders — all drugs for Substance Use Disorders →

Sponsor

Radboud University Medical Center

Who can join

18 and older, any sex, with Hepatitis C, Chronic or Substance Use Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators want to evaluate the feasibility of a decentralised hepatitis C care pathway (the Chain of Addiction Care (CAC) pathway) in several addiction care centres in the east of the Netherlands. Secondary objective: to measure the impact of hepatitis C clearance on MET (+metabolite) and BUP (+metabolite) trough levels in patients on Opioid substitution Therapy (OST). This is an exploratory, observational study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project.
Von den Hoff DW, Berden FAC, Drenth JPH, Schellekens AFA, et al · · 2022 · cited 3× · PMID 36451175 · DOI 10.1186/s13722-022-00350-1

Verify or expand the search:

Other recruiting trials for Hepatitis C, Chronic

Currently open trials in the same condition.

NCT04014179 — Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs · NA · active not recruiting
NCT04943588 — Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs · recruiting
NCT03520660 — People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents · Phase 4 · active not recruiting
NCT03200379 — Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05401136 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 2 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05401136.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing